Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
Faderl
S
S
Departments of Leukemia and Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Talpaz
M
M
Kantarjian
H M
HM
Estrov
Z
Z
D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction / Q000379:methods*
D016044:Fusion Proteins, bcr-abl